Healthpeak raises 2026 FFO outlook for third time on broad strength

What happened

Healthpeak Properties raised its full-year 2026 earnings guidance for the third time, citing strong Q3 operating results across outpatient medical, life science, and senior housing. This marks a notable shift from the lab-driven softness that weighed on same-store NOI growth to just 0.9% in Q3 2025 and drove $169 million in impairments. Management's repeated upward revisions imply that lab occupancy and leasing have stabilized, while outpatient and CCRC continue to deliver mid-single-digit NOI growth and merger synergies flow through. However, the headline lacks specifics on actual Q3 metrics, and the stock remains well below prior highs, trading around $16-17 with a 7%+ dividend yield. Investors should verify that the improved outlook is backed by sustained occupancy gains and not just one-off items or favorable capital markets.

Implication

The repeated guidance raises increase confidence that management's 2026 plan is tracking ahead of initial expectations, but the market has yet to fully price in a durable lab recovery. If lab same-store NOI turns positive and total same-store NOI reaccelerates to at least 3%, the stock could re-rate toward the mid-$20s implied by the base and bull scenarios. However, the balance sheet remains sensitive to higher-for-longer rates, with interest coverage around 1.8x and commercial paper reliance, so any unanticipated debt repricing could offset operational gains. The dividend at a ~71% AFFO payout ratio appears secure, but investors should monitor whether the improved outlook is driven by sustainable leasing or merely by lower impairments or one-time items. In sum, the news is incrementally positive but not yet a thesis-changing catalyst; maintain a cautious buy stance with attention to lab occupancy and same-store NOI trends over the next two quarters.

Thesis delta

The thesis shifts modestly positive as management's repeated outlook raises suggest that lab cyclicality may be bottoming, moving the probability of the bull case (total same-store NOI ≥3% within 12 months) higher. However, the core investment case remains unchanged: outpatient/CCRC strength and dividend yield anchor downside, while lab recovery and multiple normalization drive upside. We would increase conviction from 'potential buy' to 'buy' only upon confirmation of lab occupancy stabilization and total same-store NOI reacceleration in reported Q3 metrics.